Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care
Panelists discuss how patient-specific factors such as disease status, overall health, support systems, and treatment history are crucial considerations when determining readiness for potential transition to community settings for ongoing care.
EP: 1.The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration
EP: 2.Fast-Tracking Care: Streamlining Referrals for Quicker Treatment in Multiple Myeloma
EP: 3.Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?
EP: 4.Overcoming Challenges in Patient Referrals: Handling Reluctance and Navigating Barriers to Academic Care
EP: 5.When Is the Right Time? Navigating Key Moments for Referring Multiple Myeloma Patients to an Academic Center
EP: 6.Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care
EP: 7.Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care
EP: 8.Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled
EP: 9.Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies
EP: 10.Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
EP: 11.Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma
EP: 12.Protocols for Monitoring and Managing Long-Term Complications of Bispecific Therapy in Mutlplie Myeloma
EP: 13.Enhancing Communication Between Academic and Community Oncologists During Referral and Treatment in Multiple Myeloma.
EP: 14.Optimizing Patient Reintegration into Community Care Post-Academic Treatment of Bispecifics in Multiple Myeloma
EP: 15.Unmet Needs and Future Directions for Enhancing Bispecific Therapy Care Transitions in Multiple Myeloma
Video content above is prompted by the following:
- What patient specific factors might you consider?
- Are there any criteria that patients need to meet to be ready to move to a community setting? Does this vary between community settings?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
